Kazia Therapeutics (NASDAQ: KZIA)

Currency in -

Last close As at 20/09/2023

-1.32

−0.04 (−3.03%)

Market capitalisation

22m

Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.

Latest Insights

View More

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Iain Ross

    Chairman

  • John Friend

    CEO

  • Karen Krumeich

    CFO

Balance Sheet

Forecast net debt (US$m)

6

Forecast gearing ratio (%)

224

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.1 28.2 (77.5)
Relative 3.2 19.1 (78.4)
52 week high/low US$6.0/US$0.5

Financials

Edison Investment Research is terminating coverage on Kazia Therapeutics (KZA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.7 (3.1) (3.1) (25.09) N/A N/A
2022A 0.0 (14.9) (14.9) (110.57) N/A N/A
2023E 0.0 (19.0) (19.0) (111.41) N/A N/A
2024E 10.8 (17.2) (17.2) (82.84) N/A N/A

Thematics

thematic

Industrials

The long and winding road

thematic

MediaWatch – July 2023

thematic

Consumer

ConsumerWatch – July 2023

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free